Navigation Links
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Date:1/8/2009

CRANBURY, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr. Barer brings over 20 years of management experience and a reputation as a trusted and respected leader who has helped transform Celgene into one of the world's preeminent biopharmaceutical companies.

John F. Crowley, President and CEO of Amicus Therapeutics stated, "2009 will be an important year for the Company as we leverage our chaperone technology and continue to advance our three lead drug candidates for Fabry, Gaucher and Pompe diseases. We look forward to Dr. Barer's leadership and guidance as Amicus continues along the path of development and commercialization for new, oral treatments for a range of human genetic diseases. We welcome him to our Board."

Separately, Amicus announced today that Gregory M. Weinhoff has chosen to resign from the Board of Directors effective January 7, 2009.

About Sol. J. Barer, Ph.D.

Dr. Barer has been Chief Executive Officer of Celgene Corporation since May 1, 2006, and Chairman since January 1, 2007. He was appointed President of Celgene in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors. He previously served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from 1991 to 1994, and the Vice President, Technology, from 1987 to 1991. Dr. Barer is on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves on the Board of Trustees of the Biotechnology Council of New Jersey and is on the Board of the Brooklyn College'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
2. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
3. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
4. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
5. Amicus Therapeutics Opens Research Facility in San Diego
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
8. Amicus Therapeutics Announces First Quarter 2008 Financial Results
9. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 Outside GC, ... today announced the addition of Debbie Casey as a ... in the healthcare space. , Debbie has ... of which with Fresenius Medical Care North America in ... her extensive experience to work with Outside GC’s growing ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... PALO ALTO, Calif., Aug. 28 Avicena ... biotechnology company that,develops central nervous system therapeutics ... announced today that it has signed an,exclusive ... leading,supplier of specialty chemicals to the personal ...
... 128-compliant label,design and printing software solutions to healthcare providers, blood banks ... ... Niceware(R) International, LLC is,excited to announce that ICCBBA, Inc. granted ... labeling,software solutions that support ISBT 128-compliant data structures and bar,codes. ...
... With 3.8 Million Patients ... ... Slightly Accretive to Medco Shareholders in ... 2008, FRANKLIN LAKES, N.J. and WAKEFIELD, Mass., Aug. 28 ,Medco Health ...
Cached Biology Technology:Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 2Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 3Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 4Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 3Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 4Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 5Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 6Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 7
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... May 4, 2012 Young men who play volleyball, basketball ... more increase bone mass and might gain protection from developing ... the May issue of the Journal of Bone and ... investigation of its kind, discovered that young men who actively ...
... Sloppy shipping of a donated human retina to an ... loss has inadvertently helped uncover a previously undetected mechanism ... urge review of how millions of dollars are spent ... degeneration called choroidal neovascularization. Working at IU,s ...
... patients are treated with a drug called tamoxifen. The ... the growth signals of this hormone in cancer cells. ... their growth program: They change their behavior and shape, ... invade surrounding tissue. Scientists working with PD (Associate Professor) ...
Cached Biology News:Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis 2Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis 3Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 2Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 3Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 4MicroRNA controls malignancy and resistance of breast cancer cells 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Chromatograph/Mass Spectrometer, utilizing many of the ... offers high throughput and excellent productivity, ... ratio. Like the GCMS-QP2010 Plus, the ... for optimum separation, 20 temperature ramps, ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... XS uniquely combines a single-channel sample processing ... 8-channel bulk reagent dispenser all in one ... using disposable pipette tips, the Precision XS ... dispenser is available for transferring larger volumes. ...
Biology Products: